Is Odyssey Therapeutics, Inc. (ODTX) a Buy, Sell, or Hold?
NASDAQ : ODTX
Odyssey Therapeutics, Inc. — News
$18.82 USD
$0.21 (1.13%)
- Volume
- 9.91K
- Average Volume
- 415.24K
- Market Capitalization
- $568.9M
- P/E Ratio
- -3.49
- Dividend Yield
- 0.00%
- Price Target
- $35.00
- Year High
- $20.30
- Year Low
- $15.10
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.20
| Source | Headline |
|---|---|
|
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on hand as of March 31, 2026, together with net proceeds from the IPO, and concurrent private placement, of $464M expected to fund operations into the second half of 2028 BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today reported financial results for the first quarter ended March 31, 2026 and highlighted progress across its clinical and preclinical portfolio. “During the quarter, we continued to build meaningful momentum and made significant progress across our portfolio, including delivering clinical proof-of-concept for our oral, small molecule, RIPK2 scaffolding inhibitor, OD-001, in moderate-to-severe ulcerative colitis,” said Gary D. globenewswire.com - 2026-06-17 16:15:00 |
|
Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip
Healthcare IPO demand is coming back, but investors are not giving every new listing an easy first-day win. Odyssey Therapeutics (ODTX) and Mobia Medical (MOBI) gurufocus.com - 2026-05-11 07:31:00 |
|
Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (“Odyssey”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, today announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. globenewswire.com - 2026-05-07 20:44:00 |
